Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
Bone metastasis
Caveolin-1
Human epidermal growth factor receptors
Lipid rafts
Target therapy resistance
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
11 Oct 2024
11 Oct 2024
Historique:
received:
18
08
2024
accepted:
05
10
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
11
10
2024
Statut:
epublish
Résumé
Lipid rafts are dynamic microdomains enriched with cholesterol and sphingolipids that play critical roles in cellular processes by organizing and concentrating specific proteins involved in signal transduction. The interplay between lipid rafts, raft-associated caveolae and the human epidermal growth factor receptors has significant implications in cancer biology, particularly in breast and gastric cancer therapy resistance. This review examines the structural and functional characteristics of lipid rafts, their involvement in EGFR and HER2 signaling, and the impact of lipid rafts/CXCL12/CXCR4/HER2 axis on bone metastasis. We also discuss the potential of targeting lipid rafts and caveolin-1 to enhance therapeutic strategies against HER2-positive cancers and the impact of co-localization of trastuzumab or antibody drug conjugates with caveolin-1 on therapy response. Emerging evidence suggests that disrupting lipid raft integrity or silencing caveolin-1, through several strategies including cholesterol-lowering molecules, can influence HER2 availability and internalization, enhancing anti-HER2 targeted therapy and offering a novel approach to counteract drug resistance and improve treatment efficacy.
Identifiants
pubmed: 39394159
doi: 10.1186/s12964-024-01876-4
pii: 10.1186/s12964-024-01876-4
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
489Informations de copyright
© 2024. The Author(s).
Références
Li B, Qin Y, Yu X, Xu X, Yu W. Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis. Cell Prolif. 2022;55:e13167. https://doi.org/10.1111/cpr.13167 .
doi: 10.1111/cpr.13167
pubmed: 34939255
Simons K, Toomre D. Lipid rafts and signal transduction, Nature reviews. Mol cell Biology. 2000;1:31–9. https://doi.org/10.1038/35036052 .
doi: 10.1038/35036052
Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol. 2001;158:833–9. https://doi.org/10.1016/S0002-9440(10)64031-X .
doi: 10.1016/S0002-9440(10)64031-X
pubmed: 11238032
pmcid: 1850346
Greenlee JD, Subramanian T, Liu K, King MR. Rafting down the Metastatic Cascade: the role of lipid rafts in Cancer Metastasis, Cell Death, and clinical outcomes. Cancer Res. 2021;81:5–17. https://doi.org/10.1158/0008-5472.CAN-20-2199 .
doi: 10.1158/0008-5472.CAN-20-2199
pubmed: 32999001
Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74. https://doi.org/10.1016/j.phrs.2013.11.002 .
doi: 10.1016/j.phrs.2013.11.002
pubmed: 24269963
Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem. 2020;99:103811. https://doi.org/10.1016/j.bioorg.2020.103811 .
doi: 10.1016/j.bioorg.2020.103811
pubmed: 32278207
Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions, Nature reviews. Drug Discovery. 2023;22:101–26. https://doi.org/10.1038/s41573-022-00579-0 .
doi: 10.1038/s41573-022-00579-0
pubmed: 36344672
Rimawi MF, de Angelis C, Schiff R. Resistance to Anti-HER2 Therapies in Breast Cancer, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (2015) e157-64. https://doi.org/10.14694/EdBook_AM.2015.35.e157
Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389–400. https://doi.org/10.1038/nm.3388 .
doi: 10.1038/nm.3388
pubmed: 24202392
pmcid: 4049336
Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR targeted therapy in Non-small Cell Lung Cancer. Cancers. 2023;15. https://doi.org/10.3390/cancers15020504 .
Guidi L, Pellizzari G, Tarantino P, Valenza C, Curigliano G. Resistance to antibody-drug Conjugates Targeting HER2 in breast Cancer: Molecular Landscape and Future challenges. Cancers. 2023;15. https://doi.org/10.3390/cancers15041130 .
Wu S-G, Shih J-Y. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:38. https://doi.org/10.1186/s12943-018-0777-1 .
doi: 10.1186/s12943-018-0777-1
pubmed: 29455650
pmcid: 5817870
Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Sci (New York N Y). 1972;175:720–31. https://doi.org/10.1126/science.175.4023.720 .
doi: 10.1126/science.175.4023.720
Bagatolli LA, Mouritsen OG. Is the fluid mosaic (and the accompanying raft hypothesis) a suitable model to describe fundamental features of biological membranes? What may be missing? Front Plant Sci. 2013;4:457. https://doi.org/10.3389/fpls.2013.00457 .
doi: 10.3389/fpls.2013.00457
pubmed: 24312108
pmcid: 3826152
Yu J, Fischman DA, Steck TL. Selective solubilization of proteins and phospholipids from red blood cell membranes by nonionic detergents. J Supramolecular Struct. 1973;1:233–48. https://doi.org/10.1002/jss.400010308 .
doi: 10.1002/jss.400010308
Sezgin E, Schwille P. Fluorescence techniques to study lipid dynamics, Cold Spring Harbor perspectives in biology 3 (2011) a009803. https://doi.org/10.1101/cshperspect.a009803
Sezgin E, Levental I, Mayor S, Eggeling C. The mystery of membrane organization: composition, regulation and roles of lipid rafts, Nature reviews. Mol cell Biology. 2017;18:361–74. https://doi.org/10.1038/nrm.2017.16 .
doi: 10.1038/nrm.2017.16
Mollinedo F, Gajate C. Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of lipid rafts. J Lipid Res. 2020;61:611–35. https://doi.org/10.1194/jlr.TR119000439 .
doi: 10.1194/jlr.TR119000439
pubmed: 33715811
pmcid: 7193951
Simons K, van Meer G. Lipid sorting in epithelial cells. Biochemistry. 1988;27:6197–202. https://doi.org/10.1021/bi00417a001 .
doi: 10.1021/bi00417a001
pubmed: 3064805
Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–72. https://doi.org/10.1038/42408 .
doi: 10.1038/42408
pubmed: 9177342
Pike LJ. Rafts defined: a report on the Keystone Symposium on lipid rafts and cell function. J Lipid Res. 2006;47:1597–8. https://doi.org/10.1194/jlr.E600002-JLR200 .
doi: 10.1194/jlr.E600002-JLR200
pubmed: 16645198
Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Investig. 2002;110:597–603. https://doi.org/10.1172/JCI16390 .
doi: 10.1172/JCI16390
pubmed: 12208858
pmcid: 151114
Reeves VL, Thomas CM, Smart EJ. Lipid rafts, caveolae and GPI-linked proteins, advances in experimental medicine and biology 729 (2012) 3–13. https://doi.org/10.1007/978-1-4614-1222-9_1
Rajendran L, Le Lay S, Illges H. Raft association and lipid droplet targeting of flotillins are independent of caveolin. Biol Chem. 2007;388:307–14. https://doi.org/10.1515/BC.2007.034 .
doi: 10.1515/BC.2007.034
pubmed: 17338638
Murata M, Peränen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA. 1995;92:10339–43. https://doi.org/10.1073/pnas.92.22.10339 .
doi: 10.1073/pnas.92.22.10339
pubmed: 7479780
pmcid: 40792
Ikonen E, Parton RG. Caveolins and cellular cholesterol balance, traffic (Copenhagen, Denmark) 1 (2000) 212–7. https://doi.org/10.1034/j.1600-0854.2000.010303.x
Williams TM, Lisanti MP. The caveolin proteins, genome biology 5 (2004) 214. https://doi.org/10.1186/gb-2004-5-3-214
Solomon KR, Danciu TE, Adolphson LD, Hecht LE, Hauschka PV. Caveolin-enriched membrane signaling complexes in human and murine osteoblasts. J bone Mineral Research: Official J Am Soc Bone Mineral Res. 2000;15:2380–90. https://doi.org/10.1359/jbmr.2000.15.12.2380 .
doi: 10.1359/jbmr.2000.15.12.2380
Solomon KR, Adolphson LD, Wank DA, McHugh KP, Hauschka PV. Caveolae in human and murine osteoblasts. J bone Mineral Research: Official J Am Soc Bone Mineral Res. 2000;15:2391–401. https://doi.org/10.1359/jbmr.2000.15.12.2391 .
doi: 10.1359/jbmr.2000.15.12.2391
Quest AFG, Leyton L, Párraga M. Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease. Biochem cell Biology = Biochimie et Biol cellulaire. 2004;82:129–44. https://doi.org/10.1139/o03-071 .
doi: 10.1139/o03-071
YAMADA E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol. 1955;1:445–58. https://doi.org/10.1083/jcb.1.5.445 .
doi: 10.1083/jcb.1.5.445
pubmed: 13263332
pmcid: 2229656
Anderson RG. The caveolae membrane system, Annual review of biochemistry 67 (1998) 199–225. https://doi.org/10.1146/annurev.biochem.67.1.199
Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell. 2001;106:403–11. https://doi.org/10.1016/S0092-8674(01)00472-X .
doi: 10.1016/S0092-8674(01)00472-X
pubmed: 11525727
Gkantiragas I, Brügger B, Stüven E, Kaloyanova D, Li XY, Löhr K, Lottspeich F, Wieland FT, Helms JB. Sphingomyelin-enriched microdomains at the Golgi complex. Mol Biol Cell. 2001;12:1819–33. https://doi.org/10.1091/mbc.12.6.1819 .
doi: 10.1091/mbc.12.6.1819
pubmed: 11408588
pmcid: 37344
Lucero HA, Robbins PW. Lipid rafts-protein association and the regulation of protein activity, archives of biochemistry and biophysics 426 (2004) 208–24. https://doi.org/10.1016/j.abb.2004.03.020
Pike LJ. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta. 2005;1746:260–73. https://doi.org/10.1016/j.bbamcr.2005.05.005 .
doi: 10.1016/j.bbamcr.2005.05.005
pubmed: 15951036
Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis, American journal of physiology. Cell Physiol. 2005;288:C494–506. https://doi.org/10.1152/ajpcell.00458.2004 .
doi: 10.1152/ajpcell.00458.2004
Pereira PMR, Sharma SK, Carter LM, Edwards KJ, Pourat J, Ragupathi A, Janjigian YY, Durack JC, Lewis JS. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun. 2018;9:5137. https://doi.org/10.1038/s41467-018-07608-w .
doi: 10.1038/s41467-018-07608-w
pubmed: 30510281
pmcid: 6277446
Quest AFG, Gutierrez-Pajares JL, Torres VA. Caveolin-1: an ambiguous partner in cell signalling and cancer. J Cell Mol Med. 2008;12:1130–50. https://doi.org/10.1111/j.1582-4934.2008.00331.x .
doi: 10.1111/j.1582-4934.2008.00331.x
pubmed: 18400052
pmcid: 3865655
Cantiani L, Manara MC, Zucchini C, de Sanctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo MF, Colombo MP, Picci P, Scotlandi K. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res. 2007;67:7675–85. https://doi.org/10.1158/0008-5472.CAN-06-4697 .
doi: 10.1158/0008-5472.CAN-06-4697
pubmed: 17699771
Qian X-L, Pan Y-H, Huang Q-Y, Shi Y-B, Huang Q-Y, Hu Z-Z, Xiong L-X. Caveolin-1: a multifaceted driver of breast cancer progression and its application in clinical treatment. OncoTargets Therapy. 2019;12:1539–52. https://doi.org/10.2147/OTT.S191317 .
doi: 10.2147/OTT.S191317
pubmed: 30881011
pmcid: 6398418
Patel HH, Insel PA. Lipid rafts and caveolae and their role in compartmentation of redox signaling. Antioxid Redox Signal. 2009;11:1357–72. https://doi.org/10.1089/ars.2008.2365 .
doi: 10.1089/ars.2008.2365
pubmed: 19061440
pmcid: 2757136
Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Caveolae and signalling in cancer, Nature reviews. Cancer. 2015;15:225–37. https://doi.org/10.1038/nrc3915 .
doi: 10.1038/nrc3915
pubmed: 25801618
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network, Nature reviews. Mol cell Biology. 2001;2:127–37. https://doi.org/10.1038/35052073 .
doi: 10.1038/35052073
Yarden Y. Biology of HER2 and its importance in breast Cancer. Oncology. 2001;61:1–13. https://doi.org/10.1159/000055396 .
doi: 10.1159/000055396
pubmed: 11694782
Burgess AW, Cho H-S, Eigenbrot C, Ferguson KM, Garrett TPJ, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors, molecular cell 12 (2003) 541–52. https://doi.org/10.1016/s1097-2765(03)00350-2
Garrett TPJ, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors, molecular cell 11 (2003) 495–505. https://doi.org/10.1016/s1097-2765(03)00048-0
Roepstorff K, Thomsen P, Sandvig K, van Deurs B. Sequestration of epidermal growth factor receptors in non-caveolar lipid rafts inhibits ligand binding. J Biol Chem. 2002;277:18954–60. https://doi.org/10.1074/jbc.M201422200 .
doi: 10.1074/jbc.M201422200
pubmed: 11886870
Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci. 2002;115:1331–40. https://doi.org/10.1242/jcs.115.6.1331 .
doi: 10.1242/jcs.115.6.1331
pubmed: 11884532
Nagy P, Vereb G, Sebestyén Z, Horváth G, Lockett SJ, Damjanovich S, Park JW, Jovin TM, Szöllosi J. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci. 2002;115:4251–62. https://doi.org/10.1242/jcs.00118 .
doi: 10.1242/jcs.00118
pubmed: 12376557
Orr G, Hu D, Ozçelik S, Opresko LK, Wiley HS, Colson SD. Cholesterol dictates the freedom of EGF receptors and HER2 in the plane of the membrane. Biophys J. 2005;89:1362–73. https://doi.org/10.1529/biophysj.104.056192 .
doi: 10.1529/biophysj.104.056192
pubmed: 15908575
pmcid: 1366621
Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Rep. 2022;38:110285. https://doi.org/10.1016/j.celrep.2021.110285 .
doi: 10.1016/j.celrep.2021.110285
pubmed: 35108526
pmcid: 8865943
Kazazic M, Roepstorff K, Johannessen LE, Pedersen NM, van Deurs B, Stang E, Madshus IH. EGF-induced activation of the EGF receptor does not trigger mobilization of caveolae. Traffic. 2006;7:1518–27. https://doi.org/10.1111/j.1600-0854.2006.00487.x .
doi: 10.1111/j.1600-0854.2006.00487.x
pubmed: 16984407
Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M, Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene. 2004;23:6967–79. https://doi.org/10.1038/sj.onc.1207911 .
doi: 10.1038/sj.onc.1207911
pubmed: 15273741
Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997;272:30429–38. https://doi.org/10.1074/jbc.272.48.30429 .
doi: 10.1074/jbc.272.48.30429
pubmed: 9374534
Pereira PMR, Mandleywala K, Ragupathi A, Lewis JS. Acute Statin Treatment improves antibody Accumulation in EGFR- and PSMA-Expressing tumors, clinical cancer research. Official J Am Association Cancer Res. 2020;26:6215–29. https://doi.org/10.1158/1078-0432.CCR-20-1960 .
doi: 10.1158/1078-0432.CCR-20-1960
Nagy P, Jenei A, Kirsch AK, Szöllosi J, Damjanovich S, Jovin TM. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. J Cell Sci. 1999;112(11):1733–41. https://doi.org/10.1242/jcs.112.11.1733 .
doi: 10.1242/jcs.112.11.1733
pubmed: 10318765
Albanell J, Baselga J. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barcelona Spain: 1998). 1999;35:931–46.
doi: 10.1358/dot.1999.35.12.564040
Alawin OA, Ahmed RA, Ibrahim BA, Briski KP, Sylvester PW. Antiproliferative effects of γ-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells. J Nutr Biochem. 2016;27:266–77. https://doi.org/10.1016/j.jnutbio.2015.09.018 .
doi: 10.1016/j.jnutbio.2015.09.018
pubmed: 26507543
Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T, Berra B, Colombo I, Sorice M. Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. FEBS J. 2006;273:1821–30. https://doi.org/10.1111/j.1742-4658.2006.05203.x .
doi: 10.1111/j.1742-4658.2006.05203.x
pubmed: 16623716
Jeong J, Shin JH, Li W, Hong JY, Lim J, Hwang JY, Chung J-J, Yan Q, Liu Y, Choi J, Wysolmerski J. MAL2 mediates the formation of stable HER2 signaling complexes within lipid raft-rich membrane protrusions in breast cancer cells. Cell Rep. 2021;37:110160. https://doi.org/10.1016/j.celrep.2021.110160 .
doi: 10.1016/j.celrep.2021.110160
pubmed: 34965434
pmcid: 8762588
Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, Tylaska L, King L, Zhou D, Dushin R, Myers JS, Rosfjord E, Lucas J, Gerber H-P, Loganzo F. Caveolae-Mediated Endocytosis as a Novel mechanism of resistance to Trastuzumab Emtansine (T-DM1), molecular cancer therapeutics 17 (2018) 243–53. https://doi.org/10.1158/1535-7163.MCT-17-0403
Pereira PMR, Mandleywala K, Monette S, Lumish M, Tully KM, Panikar SS, Cornejo M, Mauguen A, Ragupathi A, Keltee NC, Mattar M, Janjigian YY, Lewis JS. Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nat Commun. 2022;13:2526. https://doi.org/10.1038/s41467-022-30142-9 .
doi: 10.1038/s41467-022-30142-9
pubmed: 35534471
pmcid: 9085816
Pereira PMR, Mandleywala K, Ragupathi A, Carter LM, Goos JACM, Janjigian YY, Lewis JS. Temporal modulation of HER2 membrane availability increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors, Journal of nuclear medicine: official publication. Soc Nuclear Med. 2019;60:1569–78. https://doi.org/10.2967/jnumed.119.225813 .
doi: 10.2967/jnumed.119.225813
Manafi-Farid R, Ataeinia B, Ranjbar S, Jamshidi Araghi Z, Moradi MM, Pirich C, Beheshti M. ImmunoPET: antibody-based PET imaging in solid tumors. Front Med. 2022;9:916693. https://doi.org/10.3389/fmed.2022.916693 .
doi: 10.3389/fmed.2022.916693
Brown EL, Shmuel S, Mandleywala K, Panikar SS, Berry N-K, Rao Y, Zidel A, Lewis JS, Pereira PMR. Immuno-PET detects antibody-drug potency on Coadministration with statins, Journal of nuclear medicine: official publication. Soc Nuclear Med. 2023;64:1638–46. https://doi.org/10.2967/jnumed.122.265172 .
doi: 10.2967/jnumed.122.265172
Rao Y, Samuels Z, Carter LM, Monette S, Panikar SS, Pereira PMR, Lewis JS. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers. Proc Natl Acad Sci USA. 2023;120:e2220413120. https://doi.org/10.1073/pnas.2220413120 .
doi: 10.1073/pnas.2220413120
pubmed: 36972439
pmcid: 10083538
Surendra Panikar S, Shmuel S, Lewis JS, Pereira PMR. PET and optical imaging of Caveolin-1 in gastric tumors. ACS Omega. 2023;8:35884–92. https://doi.org/10.1021/acsomega.3c03614 .
doi: 10.1021/acsomega.3c03614
pubmed: 37810678
pmcid: 10552508
Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92. https://doi.org/10.1016/j.cell.2011.09.024 .
doi: 10.1016/j.cell.2011.09.024
pubmed: 22000009
pmcid: 3261217
Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol cancer Research: MCR. 2008;6:446–57. https://doi.org/10.1158/1541-7786.MCR-07-0117 .
doi: 10.1158/1541-7786.MCR-07-0117
pubmed: 18337451